Bio/Pharmaceutical Outsourcing Report, August 2026
Summary
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aenova Holding GmbH
- AGC Biologics Inc
- Alcami Corp
- Aldevron LLC
- Altasciences Co Inc
- Anapharm Bioanalytics
- Apitoria Pharma Pvt Ltd
- Bachem Holding AG
- Bayer Plc
- Besins Healthcare SA
- Biocon
- BriaCell Therapeutics Corp
- Bristol Myers Squibb (BMS)
- Cambrex Corp
- Cellares Corp
- Cellipont Bioservices
- Chemo Holding SL
- Chimeric Therapeutics Ltd
- Civica Inc
- Corden Pharma International GmbH
- Dash Bio Inc
- Delpharm SAS
- ElevateBio LLC
- Eli Lilly and Co
- Emergent BioSolutions Inc
- EuroAPI Italy Srl
- EuroAPI SA
- Fujifilm Diosynth Biotechnologies UK Ltd
- Fujifilm Diosynth Biotechnologies USA Inc
- Genethon SA
- Genezen Laboratories Inc
- Hovione
- Huvepharma AD
- Imunon Inc
- Incyte Biosciences UK Ltd
- Intertek Group Plc
- Janssen-Cilag International NV
- KBI Biopharma Inc
- Kincell Bio LLC
- Kirin Holdings Co Ltd
- Landmark Bio PBLLC
- LTS Lohmann Therapie-Systeme AG
- Made Scientific
- Merck KGaA
- Moderna Inc
- MoonLake Immunotherapeutics
- National Resilience Inc
- Nikon CeLL Innovation Co Ltd
- Novartis AG
- Novartis UK Ltd
- NurExone Biologic Inc
- Occam Systems
- Oxford BioMedica Plc
- Patheon NV
- Piramal Pharma Solutions Inc
- Pluristyx Inc
- PolyPeptide SA
- Regeneron
- Richter-Helm BioLogics GmbH & Co KG
- ROVI Pharma Industrial Services SAU
- Rhythm Pharmaceuticals Inc
- Samsung Biologics Co Ltd
- Sanofi
- Santen UK Ltd
- SEQENS
- Sharp Packaging Services LLC
- Siegfried Holding AG
- Siemens AG
- Simtra US LLC
- Syngene
- Taysha Gene Therapies Inc
- Thea Group
- Unither Pharmaceuticals SAS
- Vetter Pharma-Fertigung GmbH & Co KG
- WuXi AppTec Co Ltd
- WuXi Biologics (Hong Kong) Ltd
- Xencor Inc
- Zenas BioPharma Inc
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Raybow Pharmaceutical Co Ltd

